{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T20:42:48Z","timestamp":1768682568339,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T00:00:00Z","timestamp":1380758400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T00:00:00Z","timestamp":1380758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Genet"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1038\/jhg.2013.105","type":"journal-article","created":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T06:37:42Z","timestamp":1380782262000},"page":"794-798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients"],"prefix":"10.1038","volume":"58","author":[{"given":"Akira","family":"Hirasawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeru","family":"Zama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichiro","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Makita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Susumu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Kosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Tanigawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,3]]},"reference":[{"key":"BFjhg2013105_CR1","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1023\/A:1013157727506","volume":"12","author":"ML Rothenberg","year":"2001","unstructured":"Rothenberg, M. L., Kuhn, J. G., Schaaf, L. J., Rodriguez, G. I., Eckhardt, S. G., Villalona-Calero, M. S. et al. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann. Oncol. 12, 1631\u20131641 (2001).","journal-title":"Ann. Oncol."},{"key":"BFjhg2013105_CR2","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/jnci\/83.16.1164","volume":"83","author":"S Negoro","year":"1991","unstructured":"Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K. et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl Cancer Inst 83, 1164\u20131168 (1991).","journal-title":"J. Natl Cancer Inst"},{"key":"BFjhg2013105_CR3","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1200\/JCO.1993.11.11.2194","volume":"11","author":"ML Rothenberg","year":"1993","unstructured":"Rothenberg, M. L., Kuhn, J. G., Burris, H. A. 3rd, Nelson, J., Eckhardt, J. R., Tristan-Morales, M. et al. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11, 2194\u20132204 (1993).","journal-title":"J. Clin. Oncol."},{"key":"BFjhg2013105_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1200\/JCO.2003.08.058","volume":"21","author":"CS Fuchs","year":"2003","unstructured":"Fuchs, C. S., Moore, M. R., Harker, G., Villa, L., Rinaldi, D. & Hecht, J. R. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol. 21, 807\u2013814 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFjhg2013105_CR5","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1200\/JCO.2001.19.5.1501","volume":"19","author":"U Vanhoefer","year":"2001","unstructured":"Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S. & Rustum, Y. M. Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol. 19, 1501\u20131518 (2001).","journal-title":"J. Clin. Oncol."},{"key":"BFjhg2013105_CR6","first-page":"4187","volume":"51","author":"Y Kawato","year":"1991","unstructured":"Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H. & Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51, 4187\u20134191 (1991).","journal-title":"Cancer Res."},{"key":"BFjhg2013105_CR7","doi-asserted-by":"publisher","first-page":"8170","DOI":"10.1073\/pnas.95.14.8170","volume":"95","author":"E Beutler","year":"1998","unstructured":"Beutler, E., Gelbart, T. & Demina, A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA 95, 8170\u20138174 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFjhg2013105_CR8","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","volume":"333","author":"PJ Bosma","year":"1995","unstructured":"Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A. et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert\u2019s syndrome. N. Engl. J. Med. 333, 1171\u20131175 (1995).","journal-title":"N. Engl. J. Med."},{"key":"BFjhg2013105_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0140-6736(96)91273-8","volume":"347","author":"G Monaghan","year":"1996","unstructured":"Monaghan, G., Ryan, M., Seddon, R., Hume, R. & Burchell, B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert\u2019s syndrome. Lancet 347, 578\u2013581 (1996).","journal-title":"Lancet"},{"key":"BFjhg2013105_CR10","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H. et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921\u20136926 (2000).","journal-title":"Cancer Res."},{"key":"BFjhg2013105_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/00008571-199808000-00010","volume":"8","author":"Y Ando","year":"1998","unstructured":"Ando, Y., Chida, M., Nakayama, K., Saka, H. & Kamataki, T. The UGT1A1*28 allele is relatively rare in a Japanese population. Pharmacogenetics 8, 357\u2013360 (1998).","journal-title":"Pharmacogenetics"},{"key":"BFjhg2013105_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2217\/pme.12.71","volume":"9","author":"A Hirasawa","year":"2012","unstructured":"Hirasawa, A., Akahane, T., Tanigawara, Y. & Aoki, D. Blood-direct InvaderPlus as a new method for genetic testing. Pers. Med. 9, 657\u2013663 (2012).","journal-title":"Pers. Med."},{"key":"BFjhg2013105_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2217\/pgs.10.19","volume":"11","author":"Y Fujiwara","year":"2010","unstructured":"Fujiwara, Y. & Minami, H. An overview of the recent progress in irinotecan pharmacogenetics. Pharmacogenomics 11, 391\u2013406 (2010).","journal-title":"Pharmacogenomics"},{"key":"BFjhg2013105_CR14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1023\/A:1008438109725","volume":"9","author":"Y Ando","year":"1998","unstructured":"Ando, Y., Saka, H., Asai, G., Sugiura, S., Shimokata, K. & Kamataki, T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann. Oncol. 9, 845\u2013847 (1998).","journal-title":"Ann. Oncol."},{"key":"BFjhg2013105_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1124\/dmd.31.1.108","volume":"31","author":"H Jinno","year":"2003","unstructured":"Jinno, H., Tanaka-Kagawa, T., Hanioka, N., Saeki, M., Ishida, S., Nishimura, T. et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab. Dispos. 31, 108\u2013113 (2003).","journal-title":"Drug Metab. Dispos."},{"key":"BFjhg2013105_CR16","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1124\/mol.62.3.608","volume":"62","author":"JF Gagn\u00e9","year":"2002","unstructured":"Gagn\u00e9, J. F., Montminy, V., Belanger, P., Journault, K., Gaucher, G. & Guillemette, C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol. 62, 608\u2013617 (2002).","journal-title":"Mol. Pharmacol."},{"key":"BFjhg2013105_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0925-4439(98)00013-1","volume":"1406","author":"K Yamamoto","year":"1998","unstructured":"Yamamoto, K., Sato, H., Fujiyama, Y., Doida, Y. & Bamba, T. Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. Biochim. Biophys. Acta 1406, 267\u2013273 (1998).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFjhg2013105_CR18","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2217\/pgs.10.95","volume":"11","author":"S Marsh","year":"2010","unstructured":"Marsh, S. & Hoskins, J. M. Irinotecan pharmacogenomics. Pharmacogenomics 11, 1003\u20131010 (2010).","journal-title":"Pharmacogenomics"},{"key":"BFjhg2013105_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000209335","volume":"76","author":"M Takano","year":"2009","unstructured":"Takano, M., Kato, M., Yoshikawa, T., Sasaki, N., Hirata, J., Furuya, K. et al. Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology 76, 315\u2013321 (2009).","journal-title":"Oncology"},{"key":"BFjhg2013105_CR20","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/jnci\/djm115","volume":"99","author":"JM Hoskins","year":"2007","unstructured":"Hoskins, J. M., Goldberg, R. M., Qu, P., Ibrahim, J. G. & McLeod, H. L. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst. 99, 1290\u20131295 (2007).","journal-title":"J. Natl Cancer Inst."},{"key":"BFjhg2013105_CR21","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1158\/1078-0432.CCR-10-1122","volume":"16","author":"ZY Hu","year":"2010","unstructured":"Hu, Z. Y., Yu, Q., Pei, Q. & Guo, C. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin. Cancer Res. 16, 3832\u20133842 (2010).","journal-title":"Clin. Cancer Res."},{"key":"BFjhg2013105_CR22","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1200\/JCO.2004.10.043","volume":"22","author":"JA Meyerhardt","year":"2004","unstructured":"Meyerhardt, J. A., Kwok, A., Ratain, M. J., McGovren, J. P. & Fuchs, C. S. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 22, 1439\u20131446 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFjhg2013105_CR23","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","volume":"22","author":"F Innocenti","year":"2004","unstructured":"Innocenti, F., Undevia, S. D., Iyer, L., Chen, P. X., Das, S., Kocherginsky, M. et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382\u20131388 (2004).","journal-title":"J. Clin. Oncol."},{"key":"BFjhg2013105_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0091270006295060","volume":"47","author":"RP Ramchandani","year":"2007","unstructured":"Ramchandani, R. P., Wang, Y., Booth, B. P., Ibrahim, A., Johnson, J. R., Rahman, A. et al. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. J. Clin. Pharmacol. 47, 78\u201386 (2007).","journal-title":"J. Clin. Pharmacol."},{"key":"BFjhg2013105_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1054\/bjoc.2000.1303","volume":"83","author":"G Freyer","year":"2000","unstructured":"Freyer, G., Rougier, P., Bugat, R., Droz, J. P., Marty, M., Bleiberg, H. et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure: CPT-11 F205, F220, F221 and V222 study groups. Br. J. Cancer 83, 431\u2013437 (2000).","journal-title":"Br. J. Cancer"},{"key":"BFjhg2013105_CR26","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1373\/clinchem.2004.034694","volume":"50","author":"Y Hasegawa","year":"2004","unstructured":"Hasegawa, Y., Sarashina, T., Ando, M., Kitagawa, C., Mori, A., Yoneyama, M. et al. Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin. Chem. 50, 1479\u20131480 (2004).","journal-title":"Clin. Chem."},{"key":"BFjhg2013105_CR27","unstructured":"Common terminology criteria for adverse events, version 3.0, 2006. [Cited 23 June 2013.] Available at: (\n                    http:\/\/ctep.cancer.gov\/reporting\/ctc_v30.html\n                    \n                  )."},{"key":"BFjhg2013105_CR28","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2005.03.0239","volume":"24","author":"JY Han","year":"2006","unstructured":"Han, J. Y., Lim, H. S., Shin, E. S., Yoo, Y. K., Park, Y. H., Lee, J. E. et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24, 2237\u20132244 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFjhg2013105_CR29","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/j.1349-7006.2007.00541.x","volume":"98","author":"SR Jada","year":"2007","unstructured":"Jada, S. R., Lim, R., Wong, C. I., Shu, X., Lee, S. C., Zhou, Q. et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci. 98, 1461\u20131467 (2007).","journal-title":"Cancer Sci."},{"key":"BFjhg2013105_CR30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.clpt.2004.01.010","volume":"75","author":"K Sai","year":"2004","unstructured":"Sai, K., Saeki, M., Saito, Y., Ozawa, S., Katori, N., Jinno, H. et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75, 501\u2013515 (2004).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFjhg2013105_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e328014341f","volume":"17","author":"H Minami","year":"2007","unstructured":"Minami, H., Sai, K., Saeki, M., Saito, Y., Ozawa, S., Suzuki, K. et al. Irinotecan pharmacokinetics\/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet. Genomics 17, 497\u2013504 (2007).","journal-title":"Pharmacogenet. Genomics"},{"key":"BFjhg2013105_CR32","first-page":"3723","volume":"54","author":"E Gupta","year":"1994","unstructured":"Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E. & Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54, 3723\u20133725 (1994).","journal-title":"Cancer Res."},{"key":"BFjhg2013105_CR33","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1200\/JCO.1997.15.4.1502","volume":"15","author":"E Gupta","year":"1997","unstructured":"Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E. et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J. Clin. Oncol. 15, 1502\u20131510 (1997).","journal-title":"J. Clin. Oncol."},{"key":"BFjhg2013105_CR34","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2217\/14622416.9.6.703","volume":"9","author":"CP Strassburg","year":"2008","unstructured":"Strassburg, C. P. Pharmacogenetics of Gilbert\u2019s syndrome. Pharmacogenomics 9, 703\u2013715 (2008).","journal-title":"Pharmacogenomics"},{"key":"BFjhg2013105_CR35","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2217\/pgs.12.68","volume":"13","author":"MM Dias","year":"2012","unstructured":"Dias, M. M., McKinnon, R. A. & Sorich, M. J. Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis. Pharmacogenomics 13, 889\u2013899 (2012).","journal-title":"Pharmacogenomics"}],"updated-by":[{"DOI":"10.1038\/jhg.2013.110","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2013,12,20]],"date-time":"2013-12-20T00:00:00Z","timestamp":1387497600000}}],"container-title":["Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/jhg2013105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhg2013105","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/jhg2013105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:31:10Z","timestamp":1684431070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhg2013105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,3]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["BFjhg2013105"],"URL":"https:\/\/doi.org\/10.1038\/jhg.2013.105","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/jhg.2013.110","asserted-by":"object"}]},"ISSN":["1434-5161","1435-232X"],"issn-type":[{"value":"1434-5161","type":"print"},{"value":"1435-232X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,3]]},"assertion":[{"value":"23 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2013","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been corrected since Advance Online Publication, and an erratum is also printed in this issue.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}